VKTX Stock Fluctuations: 52-Week Low of $18.92 and High of $43.15
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy VKTX?
Source: NASDAQ.COM
- Stock Price Analysis: VKTX's 52-week low is $18.92, with a high of $43.15, and the last trade at $30.23 indicates significant price fluctuations over the past year, potentially impacting investor confidence and decision-making.
- Technical Indicator Focus: The current price of $30.23 is below the 200-day moving average, suggesting potential short-term downside risk, prompting investors to closely monitor market dynamics to adjust their strategies.
- Market Sentiment Assessment: Despite substantial fluctuations within the 52-week range, the current price remains above the low point, indicating a degree of market confidence in VKTX's fundamentals, which may attract short-term traders.
- Investor Strategy Recommendation: Given VKTX's price volatility, investors should consider diversifying their portfolios to mitigate risk while keeping an eye on the company's future financial performance and market trends for more informed investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 36.010
Low
70.00
Averages
97.00
High
125.00
Current: 36.010
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ACT Capital Management Acquires New Position in Viking Therapeutics
- New Investment Position: On February 17, 2026, ACT Capital Management disclosed a new position by acquiring 206,100 shares of Viking Therapeutics worth $7.25 million, indicating confidence in the company's market potential.
- Significant Asset Allocation: This acquisition represents 5.86% of ACT Capital Management's reportable assets, highlighting Viking Therapeutics' importance within the investment portfolio and its future growth potential.
- Positive Clinical Progress: Viking's lead candidate VK2735 has shown promising results in a Phase 2 trial, with patients achieving an average weight reduction of 14.7%, propelling the program into late-stage development and indicating potential market success.
- Strong Financial Position: With approximately $706 million in cash at the end of 2025, Viking Therapeutics is well-positioned to advance its clinical pipeline and develop new therapies, enhancing its competitiveness in the biotech sector.
See More
Eli Lilly Leads U.S. Weight Loss Drug Market
- Market Share Leadership: Eli Lilly commands a 60% share of the U.S. weight loss drug market, driven by strong performance of its tirzepatide products (Mounjaro and Zepbound), solidifying its leadership in the rapidly growing weight loss sector.
- Competitive Landscape: Viking Therapeutics is advancing its VK2735 candidate through clinical trials, with strong results suggesting it could enter phase 3 trials in Q3, indicating potential competition against Lilly and Novo Nordisk's offerings, intensifying market rivalry.
- Demand and Supply Dynamics: The demand for weight loss drugs remains high, at times exceeding supply, providing Viking with an opportunity to carve out market share if its candidate successfully completes trials and gains regulatory approval.
- Investment Opportunity: Despite Eli Lilly's stock dropping about 8% this year, its forward P/E ratio has decreased to 28x, indicating a favorable investment opportunity in this weight loss leader, especially with the potential regulatory approval of its oral weight loss drug on the horizon.
See More
Eli Lilly vs. Viking Therapeutics in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly commands a 60% share in the weight loss drug market, bolstered by investments in manufacturing capacity and head-to-head studies showing superior weight loss efficacy compared to Novo Nordisk, solidifying its leadership in the U.S. market.
- Strong Product Performance: Lilly's Mounjaro and Zepbound achieved triple-digit revenue growth in the latest quarter, and despite an 8% drop in stock price this year, it trades at a forward P/E of 28, reflecting market confidence in its growth prospects.
- Clinical Trial Progress: Viking Therapeutics is advancing its VK2735 candidate into phase 3 trials, showing strong performance, and with demand for weight loss drugs exceeding supply, successful regulatory approval could carve out significant market share for the company.
- Potential Market Opportunity: Lilly's oral weight loss drug is under regulatory review and could be approved in the coming weeks, serving as a catalyst for its stock price, making this an opportune time for investors to consider shares in this weight loss drug leader.
See More
Viking Therapeutics Advances VK2735 Development Amid Mixed Trial Results
- Clinical Trial Progress: Viking Therapeutics is conducting two Phase 3 trials for VK2735, including both subcutaneous and oral formulations, with results from the oral maintenance study expected in Q3 2026, reflecting the company's ongoing confidence in the drug's potential.
- Market Reaction: According to S&P Global Market Intelligence, shares of Viking Therapeutics rose by 16.5% in February, primarily driven by the release of the company's fourth-quarter earnings, although the stock remains down by a low single-digit percentage this year compared to last.
- Safety Challenges: The previous Phase 2 VENTURE trial showed VK2735's oral formulation achieved up to 12.2% mean weight loss, but a 20% discontinuation rate due to adverse events raised concerns about its safety and tolerability, particularly gastrointestinal issues.
- FDA Feedback and Future Plans: Following feedback from an end-of-Phase 2 meeting with the FDA, the company plans to advance oral VK2735 into Phase 3 development in Q3 2026, indicating management's optimistic outlook despite the challenges faced.
See More
Viking Therapeutics Shares Surge 16.5% Following Positive Developments
- Stock Recovery: Viking Therapeutics shares rose by 16.5% in February according to S&P Global Market Intelligence, helping the stock recover in 2026, with current declines limited to low single-digit percentages, indicating market confidence in future developments.
- VK2735 Development Progress: The VK2735 program, a dual GLP-1/GIP agonist, is undergoing trials in both subcutaneous and oral forms, with the oral formulation generating significant market excitement due to its ease of use, despite disappointing top-line results from the Phase 2 trial last August.
- Clinical Trial Updates: The company initiated a maintenance and transition study in Q4, where participants will start with subcutaneous VK2735 before transitioning to a maintenance dose, with results expected in Q3 2026, reflecting ongoing confidence in the oral formulation.
- FDA Feedback and Future Plans: Following feedback from an end-of-Phase 2 meeting with the FDA, management plans to advance oral VK2735 into Phase 3 development in Q3 2026, while enrollment for the Phase 3 VANQUISH-1 trial has been completed, showcasing the company's proactive approach in clinical development.
See More
Viking Therapeutics Executive Buys Shares Amid Obesity Pipeline Progress
- Insider Confidence: Chief Commercial Officer Neil Aubuchon purchased 4,475 shares at $33.50 each on Tuesday, totaling approximately $150,000, signaling strong confidence in the company's obesity drug pipeline as it approaches critical Phase 3 trials.
- Phase 3 Trials Planned: Viking plans to launch two injectable Phase 3 trials for VK2735 in mid-2025 and aims to advance the oral formulation into Phase 3 later this year, indicating a robust strategic focus on obesity treatment development.
- Faster Enrollment Progress: The company reported that enrollment for VK2735 obesity studies has exceeded expectations, reflecting strong market interest in next-generation weight-loss therapies, which could accelerate clinical trial timelines and enhance competitive positioning.
- Market Share Strategy: Aubuchon emphasized that the company does not need to dominate the obesity market, stating that capturing just 5% to 10% market share would be deemed successful, demonstrating a clear understanding of market dynamics amid competition from Eli Lilly and Novo Nordisk.
See More
ACT Capital Management Acquires New Position in Viking Therapeutics
- New Investment Position: On February 17, 2026, ACT Capital Management disclosed a new position by acquiring 206,100 shares of Viking Therapeutics worth $7.25 million, indicating confidence in the company's market potential.
- Significant Asset Allocation: This acquisition represents 5.86% of ACT Capital Management's reportable assets, highlighting Viking Therapeutics' importance within the investment portfolio and its future growth potential.
- Positive Clinical Progress: Viking's lead candidate VK2735 has shown promising results in a Phase 2 trial, with patients achieving an average weight reduction of 14.7%, propelling the program into late-stage development and indicating potential market success.
- Strong Financial Position: With approximately $706 million in cash at the end of 2025, Viking Therapeutics is well-positioned to advance its clinical pipeline and develop new therapies, enhancing its competitiveness in the biotech sector.
See More
Eli Lilly Leads U.S. Weight Loss Drug Market
- Market Share Leadership: Eli Lilly commands a 60% share of the U.S. weight loss drug market, driven by strong performance of its tirzepatide products (Mounjaro and Zepbound), solidifying its leadership in the rapidly growing weight loss sector.
- Competitive Landscape: Viking Therapeutics is advancing its VK2735 candidate through clinical trials, with strong results suggesting it could enter phase 3 trials in Q3, indicating potential competition against Lilly and Novo Nordisk's offerings, intensifying market rivalry.
- Demand and Supply Dynamics: The demand for weight loss drugs remains high, at times exceeding supply, providing Viking with an opportunity to carve out market share if its candidate successfully completes trials and gains regulatory approval.
- Investment Opportunity: Despite Eli Lilly's stock dropping about 8% this year, its forward P/E ratio has decreased to 28x, indicating a favorable investment opportunity in this weight loss leader, especially with the potential regulatory approval of its oral weight loss drug on the horizon.
See More
Eli Lilly vs. Viking Therapeutics in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly commands a 60% share in the weight loss drug market, bolstered by investments in manufacturing capacity and head-to-head studies showing superior weight loss efficacy compared to Novo Nordisk, solidifying its leadership in the U.S. market.
- Strong Product Performance: Lilly's Mounjaro and Zepbound achieved triple-digit revenue growth in the latest quarter, and despite an 8% drop in stock price this year, it trades at a forward P/E of 28, reflecting market confidence in its growth prospects.
- Clinical Trial Progress: Viking Therapeutics is advancing its VK2735 candidate into phase 3 trials, showing strong performance, and with demand for weight loss drugs exceeding supply, successful regulatory approval could carve out significant market share for the company.
- Potential Market Opportunity: Lilly's oral weight loss drug is under regulatory review and could be approved in the coming weeks, serving as a catalyst for its stock price, making this an opportune time for investors to consider shares in this weight loss drug leader.
See More
Viking Therapeutics Advances VK2735 Development Amid Mixed Trial Results
- Clinical Trial Progress: Viking Therapeutics is conducting two Phase 3 trials for VK2735, including both subcutaneous and oral formulations, with results from the oral maintenance study expected in Q3 2026, reflecting the company's ongoing confidence in the drug's potential.
- Market Reaction: According to S&P Global Market Intelligence, shares of Viking Therapeutics rose by 16.5% in February, primarily driven by the release of the company's fourth-quarter earnings, although the stock remains down by a low single-digit percentage this year compared to last.
- Safety Challenges: The previous Phase 2 VENTURE trial showed VK2735's oral formulation achieved up to 12.2% mean weight loss, but a 20% discontinuation rate due to adverse events raised concerns about its safety and tolerability, particularly gastrointestinal issues.
- FDA Feedback and Future Plans: Following feedback from an end-of-Phase 2 meeting with the FDA, the company plans to advance oral VK2735 into Phase 3 development in Q3 2026, indicating management's optimistic outlook despite the challenges faced.
See More
Viking Therapeutics Shares Surge 16.5% Following Positive Developments
- Stock Recovery: Viking Therapeutics shares rose by 16.5% in February according to S&P Global Market Intelligence, helping the stock recover in 2026, with current declines limited to low single-digit percentages, indicating market confidence in future developments.
- VK2735 Development Progress: The VK2735 program, a dual GLP-1/GIP agonist, is undergoing trials in both subcutaneous and oral forms, with the oral formulation generating significant market excitement due to its ease of use, despite disappointing top-line results from the Phase 2 trial last August.
- Clinical Trial Updates: The company initiated a maintenance and transition study in Q4, where participants will start with subcutaneous VK2735 before transitioning to a maintenance dose, with results expected in Q3 2026, reflecting ongoing confidence in the oral formulation.
- FDA Feedback and Future Plans: Following feedback from an end-of-Phase 2 meeting with the FDA, management plans to advance oral VK2735 into Phase 3 development in Q3 2026, while enrollment for the Phase 3 VANQUISH-1 trial has been completed, showcasing the company's proactive approach in clinical development.
See More
Viking Therapeutics Executive Buys Shares Amid Obesity Pipeline Progress
- Insider Confidence: Chief Commercial Officer Neil Aubuchon purchased 4,475 shares at $33.50 each on Tuesday, totaling approximately $150,000, signaling strong confidence in the company's obesity drug pipeline as it approaches critical Phase 3 trials.
- Phase 3 Trials Planned: Viking plans to launch two injectable Phase 3 trials for VK2735 in mid-2025 and aims to advance the oral formulation into Phase 3 later this year, indicating a robust strategic focus on obesity treatment development.
- Faster Enrollment Progress: The company reported that enrollment for VK2735 obesity studies has exceeded expectations, reflecting strong market interest in next-generation weight-loss therapies, which could accelerate clinical trial timelines and enhance competitive positioning.
- Market Share Strategy: Aubuchon emphasized that the company does not need to dominate the obesity market, stating that capturing just 5% to 10% market share would be deemed successful, demonstrating a clear understanding of market dynamics amid competition from Eli Lilly and Novo Nordisk.
See More
